Modern ways to generate evidence.
Since 2016 and until 2019, the innovation fund has been promoting new forms of care within the German statutory health insurance system. New forms of managed care as well as the generation of
real world evidence is funded with an annual volume of 300 million euros. 225 million euros are provided for the promotion of new forms of managed
care and 75 million euros for real world evidence. The innovation committee set up at the
Federal Joint Committee (G-BA) defines the priorities and criteria for funding in so-called funding notices, carries out for expression-of-interest procedures and decides on the applications for
funding. The legal basis for the work of this innovation committee, are §§ 92a and 92b, Fifth Book of the Social Code (SGB V).
Read the full article here (in German) or contact us for the article
in English and for more information on the innovation funds and what you need to do to apply.
After Jens Baas, Chairman of the Board of Management of Techniker Krankenkasse (TK), gave an interview to the Sunday newspaper "Frankfurter Allgemeine Sonntagszeitung", discussions about
reforming the morbidity‑oriented risk structure compensation scheme have gained momentum.
In 2017, for the first time in six years, the Scientific Advisory Board of the Federal Insurance Office (BVA) will not review whether the selection of 80 diseases for the morbidity‑oriented risk
structure compensation scheme (Morbi-RSA) and the associated redistribution of funds is still adequate. This year, the assessment has been suspended for an important reason: due to the
discussions about the Morbi-RSA in 2016, the Federal Ministry of Health has commissioned the Scientific Advisory Board to investigate the impact of financial compensation in a special report.
This report, which will be prepared until September 30, 2017, will also include an assessment of whether the limitation to 80 diseases can be eliminated.
Read the full article here (in German) or contact us for the article in english and for more information on the morbidity‑oriented risk
structure compensation scheme in Germany.